Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Validazione Clinica TES HT100 per lo Screening delle Lesioni Cerebrali in Pazienti con Trauma Cranico Lieve o Sintomi Neurologici (TESCO)

21 settembre 2026 aggiornato da: B&B srl

Risultati Clinici TES HT100 - Validazione Clinica del Temnografo TES HT100 per lo Screening delle Lesioni Cerebrali in Pazienti con Trauma Cranico Lieve o Sintomi Neurologici Sospetti (TESCO)

The goal of this clinical study is to evaluate how accurately and safely the TES HT100 device can identify intracranial abnormalities in adult emergency department patients with mild head trauma or neurological symptoms that are not related to trauma and are not immediately life-threatening. The main questions it aims to answer are:

  • How well does TES HT100 identify patients with intracranial abnormalities compared with head CT, the reference standard?
  • Is TES HT100 safe to use in this patient population?
  • Could TES HT100 help improve patient triage and use of hospital resources in the emergency setting?

Researchers will compare the result of TES HT100 with the head CT report.

Participants will:

  • Be enrolled if they are adults presenting to the emergency department with mild head trauma or selected neurological symptoms
  • Undergo standard clinical assessment and head CT according to usual care
  • Have an additional TES HT100 examination lasting about 5 minutes, performed by trained personnel
  • Be assessed for device performance and any adverse events related to use of the device

Panoramica dello studio

Descrizione dettagliata

This is a prospective, multicenter, open-label clinical investigation evaluating the TES HT100 as a non-invasive adjunctive screening device for detection of intracranial abnormalities in adult Emergency Department patients. The study is being conducted in three centers in Italy and Poland.

TES HT100 is intended for non-invasive detection of endocerebral lesions. The device used in this investigation is TES HT model 100, equipped with software version 1.3 or later and firmware version 1.4 or later, in the same configuration planned for commercialization. The system uses non-ionizing, ultra-low-power electromagnetic waves in the 500-6500 MHz frequency range and provides a binary result indicating the presence or absence of intracranial abnormality. The examination is brief, with an overall duration of about 5 minutes.

The study is designed to evaluate the diagnostic performance and safety of TES HT100 when used in addition to standard emergency care. Participants undergo routine clinical assessment and brain CT according to usual clinical practice, and the TES HT100 examination is performed as an add-on procedure. The reference standard for performance evaluation is the brain CT report. TES HT100 is not intended to replace standard clinical assessment or CT imaging.

To reduce interpretation bias, the TES HT100 examination is performed by trained personnel who do not have access to the CT report at the time of testing, and the radiologist interpreting the CT scan is blinded to the TES HT100 result. TES HT100 examinations are performed within 24 hours before or after CT, according to site workflow.

The investigation plans to enroll approximately 850 participants overall across two clinical cohorts. The study duration is planned to be 30 months. Three TES HT100 devices, one per participating center, will be used under the same qualification and maintenance procedures.

In addition to diagnostic validation against CT, the study includes safety monitoring during device use and an exploratory assessment of the potential clinical utility of TES HT100 in emergency department triage and resource management. The overall objective is to generate clinical evidence on the performance and safety of TES HT100 as a rapid, non-invasive screening support tool in the emergency setting.

Tipo di studio

Interventistico

Iscrizione (Stimato)

850

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • CE
      • Castel Volturno, CE, Italia, 81030
        • Reclutamento
        • Pineta Grande Hospital
        • Contatto:
        • Sub-investigatore:
          • Angelo Localzo, Registered Nurse
        • Sub-investigatore:
          • Esaù Russo, Registered Nurse
        • Investigatore principale:
          • Adriana Modestina Conte, MD
        • Sub-investigatore:
          • Antonia Sorbo, MD - Radiologist
      • Gdansk, Polonia, 80-952
        • Non ancora reclutamento
        • Emergency Department, University Clinical Centre, Medical University of Gdańsk
        • Contatto:
          • Paweł Nowicki
          • Numero di telefono: +48 730 505 991
          • Email: nowicki.p@wp.pl
        • Investigatore principale:
          • Mariusz Siemiński, prof. dr hab. n. med.
      • Katowice, Polonia, 40-635
        • Reclutamento
        • Emergency Department, Leszek Giec Upper Silesian Medical Centre of the Medical University of Silesia in Katowice
        • Contatto:
        • Investigatore principale:
          • Mateusz Majewski, dr n. med.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age greater than 18 years
  • Provision of informed consent
  • Presentation to the Emergency Department with mild head injury, or
  • Presentation to the Emergency Department for non-traumatic neurological symptoms and not in a critical condition, including:
  • syncope
  • spatial disorientation and/or loss of balance
  • speech disturbance and/or facial hemi-paresis
  • visual alterations
  • memory loss and/or confusional state

Exclusion Criteria:

  • Age less than 18 years
  • Pregnant women
  • Metal plates or metal prostheses installed in the skull cap
  • Severe head trauma and/or extensive lacerated-contused areas
  • Critical condition
  • Visible skull fracture
  • Failure or inability to provide signed informed consent

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TES HT100 Examination

All enrolled participants receive standard emergency department evaluation, including head CT according to usual clinical practice, and undergo an additional TES HT100 examination as an add-on procedure. TES HT100 is evaluated against the head CT report used as the reference standard. The study includes adults with mild head injury and adults with neurological symptoms not related to head trauma and not in a critical or life-threatening condition.

A non-invasive, add-on diagnostic examination performed with the TES HT100 device to assess the presence or absence of intracranial abnormality in adult emergency department patients. The device uses ultra-low-power, non-ionizing electromagnetic waves in the 500-6500 MHz range and provides a binary on/off result. The examination lasts about 5 minutes, does not require direct contact with the patient's head, and is performed by trained personnel in addition to standard clinical evaluation and head CT.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Diagnostic accuracy of TES HT100 for detection of intracranial abnormalities
Lasso di tempo: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Diagnostic performance of TES HT100 compared with the head CT report as the reference standard, assessed by ROC-AUC and by sensitivity and specificity for identification of intracranial abnormalities.

At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT
Rate of device-related adverse events
Lasso di tempo: From TES HT100 examination through study participation completion, an average of 1 year

Incidence and type of adverse events related to the use of TES HT100 during the study.

From TES HT100 examination through study participation completion, an average of 1 year

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Operator time associated with TES HT100-supported screening
Lasso di tempo: Day 1

Descriptive evaluation of operator time associated with use of TES HT100 during emergency department screening, based on the number of TES HT100 examinations performed per participant and the approximate duration of each examination (about 5 minutes), as described in the protocol.

Day 1
Procedures associated with TES HT100-supported screening
Lasso di tempo: Day 1

Descriptive evaluation of workflow-related procedures associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol. This may include patient handling or organizational procedures required during the diagnostic pathway, such as patient transfer to a different bed or room or need for additional staff support.

Day 1
Costs associated with TES HT100-supported screening
Lasso di tempo: Day 1

Descriptive evaluation of resource use and related cost considerations associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol.

Day 1
Diagnostic performance of TES HT100 in predefined patient subgroups
Lasso di tempo: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Analysis of TES HT100 diagnostic performance, based on sensitivity and specificity versus head CT, in predefined subgroups, including younger patients, older patients, patients with or without prior injury or brain surgery, and patients with or without neurodegenerative disease.

At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Fabrizio Alfieri, B&B srl

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 dicembre 2024

Completamento primario (Stimato)

30 dicembre 2026

Completamento dello studio (Stimato)

30 gennaio 2027

Date di iscrizione allo studio

Primo inviato

14 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

18 marzo 2026

Primo Inserito (Effettivo)

24 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

De-identified participant-level data may be shared upon reasonable request, subject to ethics and institutional approval where applicable and execution of a data sharing agreement. Public sharing is not planned due to confidentiality and consent restrictions.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi